共 8 条
[1]
[2]
[3]
Pharmacological rate control of atrial fibrillation[J] Leonardo J Tamariz;Eric B Bass Cardiology Clinics 2004,
[4]
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study[J] Simon Stewart;Carole L Hart;David J Hole;John J.V McMurray The American Journal of Medicine 2002,
[5]
Factors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation: Analysis of 2012 Participants in the SPAF I-III Clinical Trials[J] Robert G. Hart;Lesly A. Pearce;Ruth McBride;Robert M. Rothbart;Richard W. Asinger Stroke: A Journal of Cerebral Circulation 1999,
[6]
Characterization of Different Subsets of Atrial Fibrillation in General Practice in France: The ALFA Study[J] Samuel Levy;Martine Maarek;Philippe Coumel;Louis Guize;Jean Lekieffre;Jean-Louis Medvedowsky;Alain Sebaoun Circulation 1999,
[7]
Double-Blind Placebo-Controlled Trial of Digoxin in Symptomatic Paroxysmal Atrial Fibrillation[J] Francis D. Murgatroyd;Sheila M. Gibson;Xie Baiyan;Sean O'Nunain;Jan D. Poloniecki;David E. Ward;Marek Malik;A. John Camm Circulation 1999,
[8]
Adjusted-dose warfarin versus low-intensity; fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial[J] The Lancet 1996,

